Multiple Myeloma (MM) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Multiple myeloma (MM) is a malignant disorder of plasma cells, constituting approximately 10% of all hematologic malignancies. The incidence of MM is slightly higher in males compared to females, and it is twice as prevalent in African-Americans as in Caucasians. The median age at diagnosis is around 65 years. Major clinical manifestations include anemia, hypercalcemia, renal failure, and an elevated risk of infections. Approximately 1-2% of patients exhibit extramedullary disease (EMD) at initial diagnosis, with 8% developing EMD later in the disease course.

Almost all cases of MM progress from an asymptomatic premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS). MGUS is found in about 5% of individuals over 50 years old, with a prevalence approximately twice as high in blacks compared to whites. The annual progression rate from MGUS to MM or a related malignancy is about 1%. Since MGUS is asymptomatic, over 50% of diagnosed individuals have had the condition for more than a decade before clinical detection. Some patients may progress through an intermediate asymptomatic stage known as smoldering multiple myeloma (SMM), which advances to MM at a rate of about 10% per year for the first five years, 3% per year over the subsequent five years, and 1.5% per year after that. This progression is influenced by cytogenetic abnormalities, with a higher risk associated with t(4;14) translocation, del(17p), and gain(1q).

Unlike other malignancies that metastasize to bone, the osteolytic lesions in MM do not exhibit new bone formation. The precise etiology of MM remains unclear; however, frequent genetic alterations and translocations involving promoter genes, particularly on chromosome 14, are common in MM and likely contribute to its pathogenesis. Oncogenes such as NRAS, KRAS, and BRAF are also implicated in plasma cell proliferation.

Several risk factors are associated with the development of MM, including:

• Age: MM is most prevalent in individuals over 65 years, though younger populations are increasingly affected.
• Race: African-Americans are twice as likely as Caucasians to develop MM.
• Immune system status: A weakened immune system increases susceptibility.
• Exposure to radiation and certain chemicals used in rubber manufacturing, woodworking, firefighting, and herbicides.
• History of other plasma cell disorders.

Historically considered fatal, recent advances in treatment have significantly improved survival rates. Treatment for MM is typically administered in phases and tailored based on the patient's overall health and age at diagnosis. Treatment modalities include:

• Chemotherapy: Utilizes anticancer drugs to kill malignant cells.
• Targeted therapies: Employ drugs that selectively target and destroy myeloma cells while sparing normal cells.
• Blood stem cell transplantation involves infusing healthy stem cells (usually autologous) into the bone marrow to replace cancer cells eliminated by high-dose chemotherapy.
• Immunotherapies: Activate the patient's immune system to attack cancer cells.
• Radiation therapy uses high-energy rays to eradicate cancer cells and inhibit new cell production. It is commonly applied to alleviate bone pain or treat plasmacytoma.
• Surgery: Generally not recommended for MM, but may be combined with radiation therapy for treating plasmacytoma.

The broad opportunity areas in Multiple myeloma include,

Closing statement: Targeting these opportunities would help drug marketers capture substantial patient share in Multiple myeloma and achieve commercial success.

Thelansis report on Multiple myeloma provides in-depth insights into the disease and patient segments, along with the areas of unmet need and drug development pipeline. The report answers key questions such as,

• What is the epidemiology for Multiple myeloma in the major markets, including the United States, Europe, Japan, China, and emerging markets?
• What are the estimated prevalence cases of Multiple myeloma in diagnosed and treated Populations?
• What are the drug treatment rates in Multiple myeloma?
• What are the KOL opinions on the unmet need areas for drug development in Multiple myeloma?
• What is the current and emerging competitive landscape in Multiple myeloma?
• What is the current market size in terms of Multiple myeloma sales?
• How will the landscape evolve over the next 10 years?

KOL Perspectives:

“For most patients, I recommend the quadruplet induction therapy of Daratumumab in combination with bortezomib, lenalidomide, and dexamethasone. When it comes to maintenance, I find that daratumumab leads to significantly improved outcomes and is well-tolerated from a convenience perspective. While I do present patients with the full array of options, most choose daratumumab."— USA – Based – Oncologist.

“Selecting induction therapy for our patients has become more nuanced than in the past. We now tailor our approach based on individual patient factors, including comorbidities and risk factors associated with high-risk multiple myeloma. In the induction setting, I prefer quadruplet regimens for younger, fit patients with particularly high-risk disease. However, for less fit patients, I still opt for triplets. Our practice may evolve based on patient outcomes in the future.”— Spain – Based - Oncologist.

About Thelansis

Thelansis specializes in pharmaceutical and biopharmaceutical business research and consulting Company, published reports across the therapeutic area, including both rare / ultra-rare and mainstream indications. Over the period, we have built a strong repository of 6,000+ bio-pharma reports covering epidemiology studies and market forecasting, as well as opportunity assessment based on the KOL interviews and conference coverage. Competitive intelligence and conference coverage throughout the phases of asset development executed by a team with a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Offerings in the orphan indications: Syndicated reports/offerings for the major markets, epidemiology, customized market research including KOL interviews, PMR surveys, pipeline research, conference coverage, market forecast models, and consulting.

The developers and marketers of drugs in orphan indications can engage Thelansis for customized market research. They can gain possible solutions for ensuring considerable market penetration for their respective therapies.

For more information, please contact:

Ankit Sahoo

Email- [email protected]

Contact No: +91- 6397-349664